Novel Magnetic Homeostatic Agents to Arrest Hemorrhage
Agency / Branch:
DOD / DARPA
"The Phase 1 SBIR project aims at developing novel approaches for controlling the so-called "non-compressible hemorrhage." The approach would involve formulating a biocompatible magnetic fluid, which would undergo a reversible liquid-solid transition at thesite of injury and seal off the broken blood vessel. This would improve the immediate management in the field of combat casualties with serious bleeding. Our initial goal is to develop means for controlling bleeding from sites located on the extremitiesand/or from lacerations involving the femoral or axillary vessels. Ultimately, our approach may be suitable for controlling bleeding from major vascular or visceral injuries in the body cavities, but this daunting problem will not be an immediate targetfor the proposed research during Phase 1. Commercial application for the technology exists in the pre-hospital care arena, including emergency vehicles at accidents and sports related injuries. Further application of the technology may include thecessation of bleeding associated with cardiac catheterization related to angioplasty and angiography, as well as in kidney dialysis"
Small Business Information at Submission:
Materials Modification, Inc.
2721-D Merrilee Drive Fairfax, VA 22031
Number of Employees: